Survodutide Bloodwork Guide: What to Track and Why
Survodutide is a dual glucagon/GLP-1 receptor agonist — and that glucagon component makes liver monitoring more important than with GLP-1-only drugs like semaglutide. The glucagon receptor directly affects hepatic metabolism, fat oxidation, and energy expenditure. Tracking the right labs tells you whether these effects are working as expected.
This guide covers which labs to run, when to run them, and what the numbers mean.
Biomarkers at a Glance
Click any bar to jump to the full breakdown.
The Testing Timeline
Baseline (before starting): Run all tests below 1-2 weeks before your first dose.
Dose escalation check (week 8-12): Retest liver enzymes, lipase, and fasting glucose. You're ramping doses during this period — this catches problems early.
Mid-protocol (week 20-24): Retest HbA1c, fasting insulin, lipid panel. By now you've reached or neared maintenance dose.
Post-protocol (2-4 weeks after finishing): Retest everything. This tells you what improvements persist.
Lab 1: Liver Enzymes — ALT & AST (Most Important for Survodutide)
Why They Matter More Here
Survodutide's glucagon receptor activation directly stimulates hepatic metabolism. This is beneficial — it clears liver fat — but it also means the liver is working harder. Monitoring ALT and AST confirms the positive trend and catches any unexpected hepatic stress.
In the Phase 2 MASH trial, survodutide dramatically reduced liver fat and improved histologic markers. Most participants saw ALT and AST improve over time.
Optimal Ranges
| Marker |
Lab Reference |
Optimal |
Watch |
| ALT |
7-56 U/L |
<25 U/L |
Rising trend or >3x baseline |
| AST |
10-40 U/L |
<25 U/L |
Rising trend or >3x baseline |
Expected pattern: ALT/AST may temporarily fluctuate early in treatment as hepatic fat oxidation increases, then trend downward as liver fat clears. A sustained upward trend is a red flag.
Lab 2: HbA1c (Glycated Hemoglobin)
What it measures: Average blood sugar over the past 2-3 months.
Why it matters: This is your primary efficacy marker for metabolic improvement. Survodutide's GLP-1 component enhances insulin secretion while the glucagon component improves hepatic glucose metabolism through liver fat reduction.
| Status |
Range |
| Optimal |
<5.0% |
| Normal |
5.0-5.6% |
| Pre-diabetic |
5.7-6.4% |
| Diabetic |
≥6.5% |
High-performance target: Below 5.0% if non-diabetic. Below 5.4% is excellent metabolic health.
HbA1cTarget: < 5.0 %
Optimal
Good
Pre-diabetic
Diabetic
Lab 3: Fasting Glucose
What it measures: Blood sugar after 8-12 hours fasting.
Why it matters: Responds faster than HbA1c — you can see changes within 2-4 weeks. Your early signal that survodutide is affecting glucose metabolism.
| Status |
Range |
| Optimal |
72-85 mg/dL |
| Normal |
70-99 mg/dL |
| Pre-diabetic |
100-125 mg/dL |
Fasting GlucoseTarget: 72–85 mg/dL
Low
Optimal
Normal
Pre-diabetic
Lab 4: Fasting Insulin
What it measures: Insulin levels after overnight fast. High fasting insulin = insulin resistance.
Why it matters: Survodutide should improve insulin sensitivity, meaning your pancreas produces less insulin to maintain glucose levels. Falling fasting insulin with stable glucose is the ideal response.
| Status |
Range |
| Optimal |
2-5 µIU/mL |
| Normal |
<25 µIU/mL |
| Concerning |
>25 µIU/mL |
Fasting InsulinTarget: 2–5 µIU/mL
Optimal
Normal
Elevated
High
Lab 5: Lipase (Pancreatic Safety)
What it measures: A pancreatic enzyme. Elevated lipase indicates pancreatic inflammation or injury.
Why it matters: GLP-1 receptor agonists carry a known risk of pancreatitis. Lipase above 3x the upper limit of normal with abdominal symptoms warrants immediate medical attention.
| Status |
Range |
| Normal |
10-73 U/L |
| Elevated |
73-219 U/L (monitor closely) |
| Critical |
>219 U/L (3x ULN — seek care) |
This is your most critical safety marker. Test at baseline and every dose escalation checkpoint.
LipaseTarget: 10–73 U/L
Normal
Elevated
Critical (3x ULN)
Lab 6: Lipid Panel
Survodutide's metabolic effects extend to lipid metabolism. As insulin resistance improves and body fat decreases, lipid profiles typically follow.
| Marker |
Optimal |
Normal |
Concerning |
| Total Cholesterol |
<180 mg/dL |
<200 mg/dL |
>240 mg/dL |
| LDL |
<100 mg/dL |
<130 mg/dL |
>160 mg/dL |
| HDL |
>60 mg/dL |
>40 mg/dL (M) / >50 (F) |
<40 mg/dL |
| Triglycerides |
<100 mg/dL |
<150 mg/dL |
>200 mg/dL |
| ApoB |
<80 mg/dL |
<100 mg/dL |
>130 mg/dL |
Triglycerides are often the most responsive marker to GLP-1/glucagon therapy — expect meaningful improvement early.
TriglyceridesTarget: < 100 mg/dL
Optimal
Normal
Borderline
High
Lab 7: TSH (Thyroid Stimulating Hormone)
What it measures: Pituitary signal to the thyroid.
Why it matters: GLP-1 receptor agonists carry a class warning for thyroid C-cell tumors based on rodent studies. While not confirmed in humans, baseline thyroid monitoring is recommended. Individuals with personal or family history of medullary thyroid carcinoma or MEN 2 should not use GLP-1 agonists.
| Status |
Range |
| Optimal |
1.0-2.0 mIU/L |
| Normal |
0.4-4.0 mIU/L |
| Investigate |
<0.4 or >4.0 mIU/L |
Consider adding calcitonin to baseline labs — a hormone produced by thyroid C-cells. Elevated calcitonin can indicate C-cell hyperplasia.
Lab 8: Kidney Function (BUN, Creatinine, eGFR)
Why it matters: Appetite suppression can lead to reduced fluid intake and dehydration, which affects kidney markers. GLP-1 agonists have shown renal protective effects in some studies, but monitoring is prudent.
| Marker |
Optimal |
Normal |
| BUN |
7-18 mg/dL |
7-20 mg/dL |
| Creatinine |
0.7-1.2 mg/dL |
0.6-1.3 mg/dL |
| eGFR |
>90 mL/min |
>60 mL/min |
eGFRTarget: > 90 mL/min
Normal
Mild decrease
Moderate decrease
CreatinineTarget: 0.7–1.2 mg/dL
Bonus: Insulin/C-Peptide
C-peptide is released 1:1 with insulin from the pancreas. It tells you how much insulin your body is actually producing (unlike fasting insulin, which can be affected by exogenous insulin use). Useful for tracking pancreatic function over time.
Putting It All Together: Sample Protocol
Week -1 (Baseline):
HbA1c, fasting glucose, fasting insulin, ALT, AST, lipase, lipid panel, TSH, calcitonin, BUN/creatinine/eGFR.
Week 8-12 (Escalation check):
Fasting glucose, ALT, AST, lipase. These catch safety issues during the critical dose-escalation period.
Week 20-24 (Mid-protocol):
HbA1c, fasting insulin, lipid panel, ALT, AST. These should show meaningful improvement by now.
Week 46+ (Post-protocol):
Retest everything from baseline. Compare each marker to starting numbers.
When to Stop: Red Flags
- Lipase >3x ULN with abdominal pain → possible pancreatitis, discontinue and seek care
- ALT/AST >5x ULN → significant hepatic stress, discontinue
- Persistent severe GI symptoms despite dose reduction → may not tolerate the drug
- Thyroid nodule or calcitonin trending up → refer to endocrinology
References
-
Blüher M, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity — a phase 2 trial. Lancet Diabetes Endocrinol. PMID:38330987
-
Sanyal AJ, et al. (2024). A Phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. PMID:38847460
-
Blüher M, et al. (2024). Dose-response effects on HbA1c and bodyweight reduction of survodutide in T2D. Diabetes Obes Metab. PMID:38095657
-
Saxena AR, et al. (2023). Phase I studies of BI 456906 safety and tolerability. Diabetes Obes Metab. PMID:36527386
This guide is for educational and informational purposes only. It is not medical advice. Survodutide is an investigational compound not approved by the FDA. The biomarker ranges described here reflect optimization targets used in functional and sports medicine — they are not diagnostic criteria. Lab results should be interpreted by a qualified healthcare provider. The Peptide Catalog is not responsible for medical decisions made based on information presented here.